A well-known pharmaceutical manufacturer Hikma Pharmaceuticals has been a partner of Megacom Ltd. since 1995.

In January 2007 Hikma Pharmaceuticals completed the acquisition of Ribosepharm GmbH (a unit of Ratiopharm GmbH), specialising in the marketing and distribution of branded generic injectable oncology products both to private practices and hospitals in Germany.

Samih Darwazah, CEO of Hikma, commented: “The acquisition of Ribosepharm provides us with an excellent platform from which to enter the large and fast-growing oncology market, which is forecast to become the second largest within the pharmaceutical industry by 2010”.